低剂量率近距离放疗治疗前列腺癌的长期生存:Royal Surrey经验
该研究基于1999-2017年前瞻性数据库2936例接受低剂量率近距离放疗的前列腺癌患者,中位随访10年,15年总生存率和前列腺癌特异性生存率分别为81%和95%。年龄、临床分期T2b/T2c-T3b及48个月PSA>1.0 ng/mL与前列腺癌死亡风险升高相关。
要点
- 15年总生存率81%,前列腺癌特异性生存率95%
- 48个月PSA>1.0 ng/mL者前列腺癌死亡风险显著升高(HR 6.8)
- T2b及T2c-T3b分期较T1a-T2a死亡风险增加
核心结论
- 低剂量率前列腺近距离放疗对局限期前列腺癌显示出优异的长期疗效。
- T2临床亚分期和48个月PSA>1.0 ng/mL是前列腺癌相关生存的强预测指标。
研究设计与样本
- 回顾性分析1999-2017年前瞻性数据库2936例接受低剂量率近距离放疗(单用或联合雄激素剥夺治疗和/或外照射放疗)的局限期前列腺癌患者。
- 主要终点为总生存率和疾病特异性生存率,采用Kaplan-Meier和竞争风险多状态模型估计。
- 采用Cox比例风险回归分析影响死亡率的临床变量,亚组分析评估植入后48个月PSA水平的预测价值。
主要发现
- 全因死亡和前列腺癌特异性死亡患病率分别为11%和2.9%。
- 中位随访时间10年(范围3-21年),中位任何原因死亡时间9年(范围3-21年)。
- 植入后15年总生存率和前列腺癌特异性生存概率分别为81%和95%。
- 15年非前列腺癌死亡和前列腺癌死亡的累积发生率分别为14%和5%。
- 前列腺癌死亡风险升高与治疗时年龄增加(HR 1.1,P<0.001)、较T1a-T2a更晚的临床分期(T2b HR 1.9,P=0.048;T2c-T3b HR 2.7,P=0.023)及48个月PSA>1.0 ng/mL(HR 6.8,P<0.001)相关。
临床怎么用
- 对于局限期前列腺癌患者,低剂量率近距离放疗可作为有效治疗选择,长期生存数据支持其疗效。
- 治疗后48个月PSA>1.0 ng/mL提示前列腺癌死亡风险显著增加,需加强随访和干预评估。
- 临床分期T2b及以上者前列腺癌死亡风险较高,应个体化制定治疗和监测策略。
局限性
- 本研究为单中心回顾性分析,尽管数据来自前瞻性数据库。
- 死亡原因注释通过内部审计补充死亡证明信息,可能存在分类偏倚。
- 亚组分析仅评估了48个月PSA的预测价值,未涉及其他时间点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the long-term treatment efficacy of low-dose-rate (LDR) brachytherapy for the treatment of localized prostate cancer. PATIENTS AND METHODS: Cause-of-death annotation in our prospective database was supplemented with death certificate information obtained via an internal audit of patients treated from 1999 to 2017 with LDR prostate brachytherapy as monotherapy or as combination with androgen deprivation therapy and/or external beam radiotherapy. Overall and disease-specific survival were the primary outcomes, estimated with Kaplan-Meier and competing risks multi-state models. Clinical variables influencing mortality were assessed with Cox proportional hazards regression in a sub-analysis of men to assess the predictive value of prostate-specific antigen (PSA) level at 48 months post implant. RESULTS: The audit process began in October 2017 and culminated in June 2020 with a curated series of 2936 patients. All-cause and prostate cancer-specific death prevalence were 11% and 2.9%, respectively. The median (range) follow-up time was 10 (3-21) years and the median (range) time to death from any cause was 9 (3-21) years. At 15 years post implant the overall and prostate cancer-specific survival probability were 81% and 95%, respectively. The 15-year cumulative incidence rates of death not due and due to prostate cancer were 14% and 5%, respectively. A greater risk of death due to prostate cancer was conferred by increasing age at therapy (hazard ratio [HR] 1.1, P < 0.001), advanced clinical stages relative to T1a-T2a (HR 1.9, P = 0.048 for T2b; HR 2.7, P = 0.023 for T2c-T3b) and a 48-month PSA level >1.0 ng/mL (HR 6.8, P < 0.001). CONCLUSION: This study constitutes the largest retrospective analyses of long-term mortality outcomes from prospectively collected prostate brachytherapy data and confirms the excellent treatment efficacy of LDR prostate brachytherapy for localized prostate cancer. T2 clinical stage subdivisions and 48-month PSA level >1.0 ng/mL appear to be strong indicators of prostate cancer-related survival.
引用
- Uribe-Lewis S, Uribe J, Bourke V, et al. Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience. BJU Int. 2021. PMID: 34448332. doi:10.1111/bju.15585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。